Thermo Fisher Scientificreason 04 of 4a reason to hold, not a barrierderived 2026-09-11accession 0000097745-26-000144
Persistent free-cash-flow generation combined with a low effective tax rate (aided by earnings in lower-tax jurisdictions and deferred-tax benefits) lets management deploy roughly $4 billion per half-year toward buybacks, dividends, and M&A without issuing equity. This capital flexibility compounds per-share value independent of top-line acceleration. The thesis fails if debt rises faster than EBITDA or if free cash flow shrinks, forcing a pause in buybacks.
the thesis · admitted · the reason above is the thesis, not printed twice
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedfour sentences · whole, uncut
the claims it rests on
“During the first six months of 2026, the company repurchased $4.00 billion of common stock (6.9 million shares)”
“On November 6, 2025, the Board authorized repurchase of up to $5.00 billion of common stock; at July 31, 2026, $1.00 billion remained available”
“Free cash flow is operating cash flow less net capital expenditures; the company uses this measure as an indication of the strength of the company”
“The company expects cash payments for income taxes of approximately $1.5 billion in 2026 and its adjusted tax rate will be approximately 11.5%”